Amicus Therapeutics, Inc. (FOLD) — 8-K Filings

8-K Filings (15)

• 8-K Filing — Dec 19, 2025
• Amicus Therapeutics Files 8-K on Financials — Nov 4, 2025 Risk: low
  On November 4, 2025, Amicus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• Amicus Therapeutics Files 8-K on Financials — Jul 31, 2025 Risk: low
  Amicus Therapeutics, Inc. filed an 8-K on July 31, 2025, reporting on its results of operations and financial condition. The filing also includes financial stat
• Amicus Therapeutics Files 8-K on Security Holder Vote & Exhibits — Jun 5, 2025 Risk: low
  On June 5, 2025, Amicus Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements. The fil
• Amicus Therapeutics Enters Material Definitive Agreement — May 1, 2025 Risk: medium
  On April 28, 2025, Amicus Therapeutics, Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial stat
• Amicus Therapeutics Files 8-K — Feb 21, 2025 Risk: low
  On February 21, 2025, Amicus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corpora
• Amicus Therapeutics Files 8-K on Financials — Feb 19, 2025 Risk: low
  On February 19, 2025, Amicus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Amicus Therapeutics Files 8-K on Financials — Jan 13, 2025 Risk: low
  Amicus Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The filing in
• Amicus Therapeutics Files 8-K on Operations and Financials — Nov 6, 2024 Risk: low
  On November 6, 2024, Amicus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• Amicus Therapeutics Appoints New Chief Medical Officer — Oct 17, 2024 Risk: medium
  On October 15, 2024, Amicus Therapeutics, Inc. announced the appointment of Dr. Brad Smith as Chief Medical Officer. Dr. Smith brings extensive experience in ra
• Amicus Therapeutics Files 8-K on Financials — Aug 8, 2024 Risk: low
  Amicus Therapeutics, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
• Amicus Therapeutics Files 8-K on Shareholder Votes and Exhibits — Jun 7, 2024 Risk: low
  Amicus Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing pertai
• Amicus Therapeutics Files 8-K on Financials — May 9, 2024 Risk: low
  On May 9, 2024, Amicus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along
• Amicus Therapeutics Files 8-K on Financial Condition — Feb 28, 2024 Risk: low
  Amicus Therapeutics, Inc. filed an 8-K on February 28, 2024, reporting on its results of operations and financial condition. The filing indicates the company's
• Amicus Therapeutics Files 8-K on Jan 7 Event; Signals Corporate Communications — Jan 8, 2024
  Amicus Therapeutics, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024. This filing indicates that the company is making

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX